Kodu・Aktsiate loetelu・MannKind Corp

MannKind Corp

Avatud

SektorTervishoid

3.96 4.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.7800000000000002

Max

3.88

Põhinäitajad
By Trading Economics
Sissetulek	-671K -17M
Müük	-22M 90M
P/E Sektori keskmine	140.5 64.641
Aktsiakasum	-0.02
Kasumimarginaal	-18.431
Töötajad	591
EBITDA	5M 2.5M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+130.26% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	353M 1.2B
Eelmine avamishind	-0.25
Eelmine sulgemishind	3.96

Uudiste sentiment

By Acuity

50%

151 / 340 Pingereas Healthcare

MannKind Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31. juuli 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30. juuli 2026, 18:41 UTC

Event

News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29. juuli 2026, 19:47 UTC

News

Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28. juuli 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27. juuli 2026, 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24. juuli 2026, 21:01 UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23. juuli 2026, 10:36 UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22. juuli 2026, 21:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21. juuli 2026, 22:11 UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Võrdlus sarnastega

Hinnamuutus

MannKind Corp Prognoos

Hinnasiht

By TipRanks

130.26% tõus

12 kuu keskmine prognoos

Keskmine 8.75 USD 130.26%

Kõrge 14 USD

Madal 4.75 USD

Põhineb 6 Wall Streeti analüütiku instrumendi MannKind Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi MannKind Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.